Survival summary data in Jo-1 and non-Jo-1 antisynthetase patients
| Survival (in years) | Jo-1 | Non-Jo-1 | EJ | PL-7 | OJ | PL-12 | KS |
|---|---|---|---|---|---|---|---|
| 5-year survival from diagnosis (95% CI) | 90% (81.4 to 94.7) | 70% (56.9 to 79.6) | 47% (12.0 to 76.3) | 67% (41.8 to 82.6) | 60% (12.6 to 88.2) | 91% (66.2 to 97.9) | 100% (no patient died) |
| 10-year survival from diagnosis (95% CI) | 75% (61.3 to 84.5) | 47% (31.0 to 61.7) | * | 31% (11.7 to 52.4) | * | 58% (6.5 to 80.3) | 100% (no patient died) |
| Median cumulative survival | 15 years (IQR 8.3–22.4) | 9 years (IQR 5.1–19.0) | 1.9 years (IQR 0.2–17.7) | 6.4 years (IQR 4.2–21.6) | 18.0 years (IQR 0.6–18.0) | 19.0 years (7.2–20.1) | * (no patient died) |
| Median event free survival | 15 years (IQR 7.8–20.6) | 8 years (IQR 4.2–19.0) |
*Too few observations to provide meaningful data.